Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411548 · ClinicalTrials.gov registry record · NA
InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT06411548: Completed NA study, sponsored by University of Virginia.
NCT06411548 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06411548, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a 24-hour, randomized, crossover, single-center trial where participants are randomized to either start with the InsuLearn intervention or the usual care (UC) intervention. In the InsuLearn intervention, insulin doses are optimized using data collected in a 4-weeks at home data collection period.
Primary Outcome
The primary outcome will be, per protocol (\>70% of CGM values available after a meal), analysed using repeated measures ANOVA within-group contrast: i.e., InsuLearn vs. usual care.
Interventions
- DEVICE InsuLearn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2025-10-17 |
| Phase | NA |
What the finished NCT06411548 record still lists
NCT06411548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which InsuLearn is the first listed.
NCT06411548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06411548 about?
NCT06411548 is a clinical study titled "InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy". This is a 24-hour, randomized, crossover, single-center trial where participants are randomized to either start with the InsuLearn intervention or the usual care (UC) intervention. In the InsuLearn intervention, insulin doses are optimized using data collected in a 4-weeks at home data collection pe...
What is the current status of trial NCT06411548?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2025-03-27. Estimated completion is 2025-10-17.
What interventions are being tested in trial NCT06411548?
The interventions under investigation include: InsuLearn (DEVICE).
Who is sponsoring clinical trial NCT06411548?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06411548's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI